Speaker illustration

Associate Professor Thomas A Zelniker

Medical University of Vienna, Vienna (Austria)

Member of:

European Society of Cardiology

Effect of dapagliflozin on cardiovascular outcomes in patients with type 2 diabetes according to baseline renal function and albuminuria status: Insights from DECLARE-TIMI 58

Event: ESC Congress 2019

Topic: Antidiabetic Pharmacotherapy

Session: New frontiers: SGLT2 inhibitors in cardiorenal disease


ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb